122 related articles for article (PubMed ID: 36724958)
1. Use of Iontophoresis Technology for Transdermal Delivery of a Minimal mRNA Vaccine as a Potential Melanoma Therapeutic.
Husseini RA; Abe N; Hara T; Abe H; Kogure K
Biol Pharm Bull; 2023; 46(2):301-308. PubMed ID: 36724958
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Iontophoretic-Delivered Polyplex Vaccine on Melanoma Regression.
Husseini RA; Fukuta T; Ozono M; Hasan AA; Megrab NAE; Kogure K
Biol Pharm Bull; 2023; 46(3):494-504. PubMed ID: 36858579
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer vaccination by transdermal delivery of antigen peptide-loaded nanogels via iontophoresis.
Toyoda M; Hama S; Ikeda Y; Nagasaki Y; Kogure K
Int J Pharm; 2015 Apr; 483(1-2):110-4. PubMed ID: 25681719
[TBL] [Abstract][Full Text] [Related]
4. Iontophoresis-mediated direct delivery of nucleic acid therapeutics, without use of carriers, to internal organs via non-blood circulatory pathways.
Hasan M; Fukuta T; Inoue S; Mori H; Kagawa M; Kogure K
J Control Release; 2022 Mar; 343():392-399. PubMed ID: 35131371
[TBL] [Abstract][Full Text] [Related]
5. mRNA-encoded, constitutively active STING
Tse SW; McKinney K; Walker W; Nguyen M; Iacovelli J; Small C; Hopson K; Zaks T; Huang E
Mol Ther; 2021 Jul; 29(7):2227-2238. PubMed ID: 33677092
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment.
Fukuta T; Oshima Y; Michiue K; Tanaka D; Kogure K
J Control Release; 2020 Jul; 323():323-332. PubMed ID: 32360305
[TBL] [Abstract][Full Text] [Related]
7. Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis.
Hasan M; Khatun A; Kogure K
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140019
[TBL] [Abstract][Full Text] [Related]
8. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
[TBL] [Abstract][Full Text] [Related]
9. [Drug Delivery to Various Body Organs via Non-blood Circulatory Pathway].
Kogure K; Fukuta T
Yakugaku Zasshi; 2020; 140(5):611-615. PubMed ID: 32378660
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
11. A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model.
Liu H; Geng S; Feng C; Xie X; Wu B; Chen X; Zou Q; Wang S; Cui J; Xing R; Li W; Lu Y; Wang B
Hum Vaccin Immunother; 2013 Oct; 9(10):2196-202. PubMed ID: 24051432
[TBL] [Abstract][Full Text] [Related]
12. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
[TBL] [Abstract][Full Text] [Related]
13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
14. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
15. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy.
Duong HTT; Yin Y; Thambi T; Nguyen TL; Giang Phan VH; Lee MS; Lee JE; Kim J; Jeong JH; Lee DS
Biomaterials; 2018 Dec; 185():13-24. PubMed ID: 30216806
[TBL] [Abstract][Full Text] [Related]
16. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.
Chang X; Xia CQ
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):46-52. PubMed ID: 26545782
[TBL] [Abstract][Full Text] [Related]
17. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
18. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
[TBL] [Abstract][Full Text] [Related]
20. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
